Inspire Medical Systems (NYSE:INSP) Upgraded by Zacks Research to Hold Rating

Inspire Medical Systems (NYSE:INSP) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Wells Fargo & Company decreased their price target on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 5th. Robert W. Baird reduced their price objective on Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 5th. Mizuho decreased their target price on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Evercore downgraded Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 target price on the stock. in a report on Tuesday, June 23rd. Finally, Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price target on the stock. in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $81.05.

Inspire Medical Systems Price Performance

NYSE INSP opened at $50.14 on Monday. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The firm has a market capitalization of $1.44 billion, a P/E ratio of 11.17, a P/E/G ratio of 5.01 and a beta of 0.71. The business’s 50-day simple moving average is $44.31 and its 200-day simple moving average is $61.08.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The firm had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. During the same period in the previous year, the company posted $0.10 earnings per share. Inspire Medical Systems’s revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities research analysts expect that Inspire Medical Systems will post 0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Inspire Medical Systems

Hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC grew its holdings in Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares in the last quarter. Havemeyer Place LP bought a new position in Inspire Medical Systems in the 4th quarter valued at about $39,000. V Square Quantitative Management LLC acquired a new position in Inspire Medical Systems during the 4th quarter valued at about $40,000. Smartleaf Asset Management LLC increased its stake in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after buying an additional 205 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in shares of Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 130 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.